USDA Grants Expanded Approval for Elanco's Canine Parvovirus Monoclonal Antibody, Enhancing Preventative Measures for Puppies Across the Nation
Elanco Animal Health Inc. has announced a significant regulatory milestone with the U.S. Department of Agriculture (USDA) granting expanded approval for its Canine Parvovirus Monoclonal Antibody (CPMA). This approval allows the use of CPMA for passive immunity, providing veterinarians with a preventative option to protect puppies exposed to the deadly canine parvovirus. In line with their mission "Defend Puppies. Defeat Parvo.", Elanco has also donated over $3 million worth of CPMA to 2,300 clinics and shelters in high parvo risk areas, broadening access to this life-saving treatment. This initiative has already seen success, with the largest recorded group of 27 parvo-infected puppies saved at the SPCA of Brevard Adoption Center in Florida.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Elanco Animal Health Inc. published the original content used to generate this news brief on June 27, 2025, and is solely responsible for the information contained therein.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。